Tech Company Financing Transactions
Boulevard Bio Funding Round
On 8/12/2026, Boulevard Bio raised $65 million in investment from Deerfield Management Company and private investors.
Transaction Overview
Company Name
Announced On
8/12/2026
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
345 Park Avenue South
New York, NY 10010
USA
New York, NY 10010
USA
Phone
Undisclosed
Website
Email Address
Overview
Boulevard Bio is a clinical-stage, precision immunology company built to change the course of B cell-driven autoimmune diseases with targeted multi-specific medicines designed to set new therapeutic standards. Grounded in a deep understanding of B cell biology, Boulevard's medicines aim to modify disease at its source, delivering what patients expect and deserve, from durable disease control to the prospect of a cure.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mahesh Karande
Chief Medical Officer
Neil Solomons
Chief Scientific Officer
Susannah Barbee
Vice President
Ohn Chow
VP - Operations
Rupal Kalapanda
VP - Operations
Jifeng Zhang
Browse more venture capital transactions:
Prev: 8/12/2026: Reservoir venture capital transaction
Next: 8/12/2026: Remepy venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs